Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

NCT00922363 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis

Interventions

BIOLOGICAL: 50 µg Ag85B-ESAT-6 alone
BIOLOGICAL: 50 µg Ag85B-ESAT-6 + 125/25 µg CAF01
BIOLOGICAL: 50 µg Ag85B-ESAT-6 + 313/63 µg CAF01
BIOLOGICAL: 50 µg Ag85B-ESAT-6 + 625/125 µg CAF01

Sponsor

Statens Serum Institut